NCT00354926 - Safety and Efficacy Study of an Anti-CD20 Monoclonal Antibody (AME-133v) to Treat Non-Hodgkin's Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2006

Primary Completion Date

January 31, 2009

Study Completion Date

January 31, 2009

Conditions

Non-Hodgkin's Lymphoma

Interventions

BIOLOGICAL

AME-133v (LY2469298)

IV 4X weekly X 4

Trial Locations (11)

University of Pittsburgh Medical Center, Pittsburgh

Fox Chase Cancer Center, Philadelphia

University of Virginia Health System, Charlottesville

University of Alabama Medical Center, Birmingham

Sarah Cannon Research Institute, Nashville

Cleveland Clinic Foundation, Cleveland

University of Iowa, Iowa City

Rush University Medical Center, Chicago

Nevada Cancer Institute, Las Vegas

UCLA Medical Hematology and Oncology, Los Angeles

Stanford University Medical Center, Stanford